New cocktail aims to make liver cancer operable
NCT ID NCT06405061
First seen May 30, 2026 · Last updated Jun 13, 2026 · Updated 4 times
Summary
This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and reduce the chance of cancer coming back. About 40 adults with a specific stage of liver cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
Third Central Hospital of Tianjin
Tianjin, Tianjin Municipality, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
-
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.